Latest Safety News

Critical Resources Limited has validated its amorphous solid-state electrolyte, demonstrating stable lithium-metal interface performance over 1,200 hours and efficient ionic conductivity at room temperature, marking a significant step in solid-state battery development.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

West African Resources has reported a robust A$567 million net profit after tax for 2025, driven by strong gold production and operational cash flow. The successful ramp-up of the Kiaka gold production centre and sustained output from Sanbrado underpin the company’s positive outlook for 2026.

WA Kaolin Limited reported a $5.06 million half-year loss despite a 257% revenue surge, grappling with operational setbacks and regulatory challenges. The company’s recent debt restructuring and trading suspension signal a critical juncture as it seeks to stabilise and recapitalise.

Percheron Therapeutics has announced a $2.2 million non-renounceable entitlement offer at a 20% discount, including free options, to fund the next phase of its lead oncology asset HMBD-002.

Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.

ABx Group has announced a breakthrough with its second mixed rare earth carbonate sample from Tasmania’s Deep Leads deposit, boasting higher heavy rare earth content and fewer impurities. This advancement enhances project flexibility and strengthens ABx’s position in the competitive rare earths market.

Dimerix Limited is set to conduct a blinded statistical review of its pivotal Phase 3 ACTION3 study in March 2026, aiming to confirm the trial remains powered to demonstrate the primary endpoint of proteinuria reduction in FSGS patients.

MC Mining reports a modest improvement in half-year losses despite declining coal production and revenue, while advancing its Makhado Project and suspending Uitkomst operations to curb cash losses.

Emperor Energy has successfully raised $17.5 million to advance drilling of its Judith-2 appraisal well, aiming to unlock a major gas resource in Victoria’s Gippsland Basin. The capital raise underscores strong investor confidence as the company moves closer to proving commercial gas flow rates.

EVE Health Group has raised $0.9 million to advance its pharmaceutical reformulation programs targeting global markets worth over US$30 billion. The funding will support development of improved delivery technologies for medicines nearing patent expiry.